SPI1 and myeloproliferative neoplasm: The specific mechanism of action is that the deletion of USP22 results in reduced levels of PU.1 under Kras mutation-driven MPN conditions, whereas previous studies have shown that reduced PU.1 expression and activity is common in mouse and human acute myeloid leukemia (AML) cases.